Biotech · Private company
ProSciento, Inc.
Track this companyFree. Adds ProSciento, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials70 recruiting or active
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Clinical trials7
- Pharmacokinetic and Pharmacodynamic Effects of Insulex® R in Comparison to Humulin® R in Healthy SubjectsPHASE1 · COMPLETED · started Oct 24, 2024ClinicalTrials.gov NCT07364669 · fetched Nov 12, 2026
- Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of MBX 1416 in Healthy SubjectsPHASE1 · COMPLETED · started Sep 18, 2023ClinicalTrials.gov NCT06036784 · fetched Nov 12, 2026
- A Comparison of Postprandial Glucose After a MMTT, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study in Subjects With Type 1 DiabetesPHASE2 · COMPLETED · started Jun 17, 2021ClinicalTrials.gov NCT04956263 · fetched Nov 12, 2026
- Pilot Study to Assess the Effects of Hepatic Ultrasound Insonification on Subjects With T2DMNA · COMPLETED · started Jul 30, 2020ClinicalTrials.gov NCT04502212 · fetched Nov 12, 2026
- A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASHPHASE1_PHASE2 · COMPLETED · started Jul 29, 2019ClinicalTrials.gov NCT04048135 · fetched Nov 12, 2026
- A Study of FT 4101 in Overweight/Obese Participants With Non-alcoholic SteatohepatitisPHASE1_PHASE2 · TERMINATED · started May 17, 2019ClinicalTrials.gov NCT04004325 · fetched Nov 12, 2026
- Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)PHASE1 · COMPLETED · started Aug 28, 2017ClinicalTrials.gov NCT03261739 · fetched Nov 12, 2026